Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYRX CryoPort	$8.66 -0.7%	$7.52	$4.58 ▼ $9.48	$433.61M	1.88	538,187 shs	469,714 shs
KOD Kodiak Sciences	$9.50 +0.2%	$5.82	$1.92 ▼ $11.60	$501.81M	2.41	446,422 shs	978,024 shs
LIMN Liminatus Pharma	$3.34 -13.5%	$6.93	$3.28 ▼ $33.66	$86.87M	N/A	532,758 shs	464,438 shs
TNXP Tonix Pharmaceuticals	$36.05 -1.3%	$41.37	$6.76 ▼ $130.00	$316.16M	1.7	1.41 million shs	1.54 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYRX CryoPort	-0.80%	+2.71%	+21.28%	+42.02%	-7.14%
KOD Kodiak Sciences	-15.73%	+11.27%	+71.74%	+167.80%	+257.74%
LIMN Liminatus Pharma	-2.77%	-11.26%	-28.78%	+385,999,900.00%	+385,999,900.00%
TNXP Tonix Pharmaceuticals	-8.83%	-38.87%	-22.13%	+28.94%	-17.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYRX CryoPort	4.1047 of 5 stars	4.5	1.0	0.0	0.0	3.3	3.3	1.9
KOD Kodiak Sciences	3.1412 of 5 stars	2.0	1.0	0.0	4.6	2.4	3.3	0.0
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	2.6717 of 5 stars	3.5	2.0	0.0	0.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYRX CryoPort	3.00	Buy	$12.00	36.52% Upside
KOD Kodiak Sciences	2.00	Hold	$11.75	30.61% Upside
LIMN Liminatus Pharma	0.00	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	3.00	Buy	$70.00	95.59% Upside

Current Analyst Ratings Breakdown

Latest LIMN, CYRX, KOD, and TNXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $5.00
8/14/2025	KOD Kodiak Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underweight ➝ Underweight	$4.00 ➝ $7.00
8/14/2025	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$15.00
8/6/2025	CYRX CryoPort	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2025	CYRX CryoPort	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Weight ➝ Overweight	$15.00
8/6/2025	CYRX CryoPort	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$16.00
7/22/2025	CYRX CryoPort	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
7/7/2025	CYRX CryoPort	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $10.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYRX CryoPort	$228.38M	1.93	N/A	N/A	$9.53 per share	0.92
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$1.33 per share	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	$10.09M	31.11	N/A	N/A	$19.17 per share	1.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYRX CryoPort	-$114.76M	$1.33	6.61	N/A	N/A	37.21%	-9.79%	-5.42%	11/6/2025 (Estimated)
KOD Kodiak Sciences	-$176.21M	-$3.80	N/A	N/A	N/A	N/A	-155.27%	-63.29%	N/A
LIMN Liminatus Pharma	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	-$130.04M	-$39.47	N/A	N/A	N/A	-828.22%	-57.93%	-51.04%	N/A

Latest LIMN, CYRX, KOD, and TNXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	-$1.03	-$0.02	-$1.03	N/A	N/A
8/11/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.10	-$3.86	-$0.76	-$3.86	$2.60 million	$2.00 million
8/5/2025	Q2 2025	CYRX CryoPort	-$0.20	-$0.29	-$0.09	$2.05	$41.74 million	$45.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYRX CryoPort	0.39	16.24	15.47
KOD Kodiak Sciences	N/A	3.48	3.48
LIMN Liminatus Pharma	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	7.53	7.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYRX CryoPort	92.90%
KOD Kodiak Sciences	89.06%
LIMN Liminatus Pharma	N/A
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
CYRX CryoPort	10.10%
KOD Kodiak Sciences	45.90%
LIMN Liminatus Pharma	N/A
TNXP Tonix Pharmaceuticals	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYRX CryoPort	1,186	50.07 million	45.01 million	Optionable
KOD Kodiak Sciences	90	52.82 million	28.58 million	Optionable
LIMN Liminatus Pharma	N/A	26.01 million	N/A	N/A
TNXP Tonix Pharmaceuticals	50	8.77 million	8.76 million	Not Optionable

LIMN, CYRX, KOD, and TNXP Headlines

Recent News About These Companies

SA analyst upgrades/downgrades: HD, AAPL, TMUS, TNXP

4 hours ago | msn.com

Tonix Pharma Announces FDA Approval of Tonmya

August 19 at 8:22 PM | msn.com

Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)

August 19 at 12:31 PM | seekingalpha.com

Tonix Pharmaceuticals Reports Q2 2025 Financial Results

August 19 at 10:19 AM | msn.com

FDA Approves New Fibromyalgia Drug, But Tonix Shares Slide

August 18 at 2:29 PM | msn.com

Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years

August 18 at 2:29 PM | finance.yahoo.com

Tonix Pharmaceuticals (TNXP) Faces Volatility Despite FDA Approval

August 18 at 1:20 PM | gurufocus.com

FDA Approves New Fibromyalgia Drug, Tonix Shares Climb

August 18 at 9:28 AM | msn.com

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

August 18 at 9:28 AM | msn.com

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Stock Holdings Reduced by Virtu Financial LLC

August 18 at 4:22 AM | marketbeat.com

Noble Financial Has Pessimistic Outlook of TNXP Q3 Earnings

August 17 at 8:27 AM | marketbeat.com

FDA approves first new fibromyalgia treatment in over 15 years

August 16, 2025 | thepharmaletter.comT

Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up - Time to Buy?

August 16, 2025 | marketbeat.com

Tonix Secures Fibromyalgia Approval - What Investors Should Know

August 16, 2025 | seekingalpha.com

Tonix Pharma Gains FDA Approval for Tonmya

August 16, 2025 | msn.com

Noble Financial Has Negative Estimate for TNXP Q3 Earnings

August 16, 2025 | americanbankingnews.com

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

August 15, 2025 | manilatimes.netM

Tonix Pharmaceuticals jumps 17% to $60.13 after FDA approval of Tonmya

August 15, 2025 | msn.com

Tonix Pharmaceuticals stock halted ahead of FDA approval news

August 15, 2025 | investing.com

Form 8K Tonix Pharmaceuticals Holding Corp For: 15 August

August 15, 2025 | investing.com

Tonix Pharmaceuticals (TNXP) Secures FDA Approval for Fibromyalgia Drug

August 15, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN, CYRX, KOD, and TNXP Company Descriptions

CryoPort NASDAQ:CYRX

$8.66 -0.06 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$8.38 -0.29 (-3.29%)

As of 04:49 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Kodiak Sciences NASDAQ:KOD

$9.50 +0.02 (+0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$9.30 -0.20 (-2.05%)

As of 06:50 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Liminatus Pharma NASDAQ:LIMN

$3.34 -0.52 (-13.47%)

As of 04:00 PM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Tonix Pharmaceuticals NASDAQ:TNXP

$36.05 -0.48 (-1.31%)

Closing price 04:00 PM Eastern

Extended Trading

$36.17 +0.13 (+0.35%)

As of 07:58 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time